Trial Profile

Phase Ib Study of Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer (ABC Trial)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 19 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; BCG (Primary)
Indications Bladder cancer
Focus Adverse reactions
Acronyms ABC Trial; OU-SCC-ABC

Most Recent Events

08 Nov 2023 Status changed from active, no longer recruiting to completed.
21 Nov 2022 Planned End Date changed from 1 Feb 2023 to 1 Jun 2023.
13 Sep 2021 Results (n=18) assessing safety and tolerability of a novel intense weekly dosing regimen of avelumab during BCG induction for patients with BCG-unresponsive NMIBCpresented at the 116th Annual Meeting of the American Urological Association

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com